Economic and outcomes aspects of venous thromboembolic disease. [Review]
Citation: Critical Care Clinics. 28(1):113-23, vii, 2012 Jan.PMID: 22123103Institution: MedStar Washington Hospital CenterDepartment: Medicine/Pulmonary-Critical CareForm of publication: Journal ArticleMedline article type(s): Journal Article | ReviewSubject headings: *Intensive Care/ec [Economics] | *Venous Thromboembolism/ec [Economics] | Health Policy | Humans | Intensive Care Units/ec [Economics] | Intensive Care/mt [Methods] | Randomized Controlled Trials as Topic | Risk Factors | Treatment Outcome | United States/ep [Epidemiology] | Venous Thromboembolism/ep [Epidemiology] | Venous Thromboembolism/pc [Prevention & Control]Year: 2012Local holdings: Available online from MWHC library: 1996 - presentISSN:- 0749-0704
Item type | Current library | Collection | Call number | Status | Date due | Barcode |
---|---|---|---|---|---|---|
Journal Article | MedStar Authors Catalog | Article | 22123103 | Available | 22123103 |
Available online from MWHC library: 1996 - present
Critically ill patients clearly face an increased risk for developing venous thromboembolic disease (VTE). Upon admission, all critical care patients should be immediately assessed for and prescribed VTE prophylaxis as it can significantly reduce VTE occurrence, its potential sequelae,and costs associated with VTE treatment. The financial burden associated with VTE is substantial. Longer ICU and hospital lengths of stay, pharmacy costs, and further outpatient management all contribute considerably to the economic burden of disease. The importance of this healthcare issue should motivate hospital administrators and physicians to systematically initiate thromboprophylaxis in all ICU patients.
English